ADVM 053

Drug Profile

ADVM 053

Alternative Names: ADVM-053; ANN 002

Latest Information Update: 19 May 2017

Price : $50

At a glance

  • Originator Weill Cornell Medical College
  • Developer Adverum Biotechnologies
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hereditary angioedema

Most Recent Events

  • 09 May 2017 Adverum Biotechnology intends to file an IND application for hereditary angioedema
  • 06 Mar 2017 Adverum plans IND-enabling toxicology studies for Hereditary angioedema and intends to enter into a discussion with US FDA in the first half of 2017
  • 06 Jan 2017 Preclinical trials in Hereditary angioedema in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top